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Abstract
14-3-3s is frequently lost in human breast cancers by genetic deletion or promoter methylation. We have now investigated
the involvement of 14-3-3s in the termination of NF-kB signal in mammary cells and its putative role in cancer relapse and
metastasis. Our results show that 14-3-3s regulates nuclear export of p65-NF-kB following chronic TNFa stimulation.
Restoration of 14-3-3s in breast cancer cells reduces migration capacity and metastatic abilities in vivo. By microarray
analysis, we have identified a genetic signature that responds to TNFa in a 14-3-3s-dependent manner and significantly
associates with different breast and other types of cancer. By interrogating public databases, we have found that over-
expression of this signature correlates with poor relapse-free survival in breast cancer patients. Finally, screening of 96
human breast tumors showed that NF-kB activation strictly correlates with the absence of 14-3-3s and it is significantly
associated with worse prognosis in the multivariate analysis. Our findings identify a genetic signature that is important for
breast cancer prognosis and for future personalized treatments based on NF-kB targeting.
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Introduction
Breast cancer is the most common cancer that affects women in
western countries, and metastasis is a fatal consequence of this
disease [1]. The identification of the mechanisms involved in the
survival of breast cancer cells and their ability to colonize distant
tissues is a crucial issue for personalized cancer therapy and
improvement of patient treatment. However, complexities of the
cellular interactions and the molecular components that are
involved in breast cancer progression and metastasis have
challenged the significance of new discoveries in this field [2]. A
majority of the metastases occurring in breast cancer patients arise
in the bone and are generally osteolytic, involving the mobilization
of osteoclasts that cause bone resorption, with severe pain, bone
fractures, nerve compression and hypercalcemia [3,4,5]. Interest-
ingly, a particular characteristic of the bone microenvironment is
not only that it represents a bona-fide stem cell niche for
hematopoietic cells, but also that it contains immune cells that are
a source of inflammatory cytokines. Inflammation is a major
contributor to carcinogenesis, being Nuclear Factor-kB (NF-kB)
the master transducer of inflammatory signals [6]. Breast cancer
has repetitively been linked to high NF-kB activity
[7,8,9,10,11,12], which regulates genes associated with tumor
invasion and metastasis such as Maspin [13] and GM-CSF [9].
NF-kB activation is triggered by different extracellular stimuli such
as inflammatory cytokines, EGF or RANKL [14,15,16,17], a
finding that is the base for using antibodies against TNFa, soluble
TNFa receptors or RANKL inhibitors in patients with bone-
metastasis [18,19]. However, alterations in inhibitory factors of
NF-kB signal also contribute in maintaining high NF-kB activity
in cancer cells [20].
14-3-3 is a highly conserved family of adaptor proteins that
regulate multiple signal transduction pathways by regulating
activity (e.g. Raf, JNK) [21,22] or promoting the nuclear export
of pre-phosphorylated substrates (e.g. FOXO, CDC25, HDAC or
regulators of mTOR) [23,24,25,26]. We previously demonstrated
that different 14-3-3 members bind and facilitate nuclear export of
NF-kB complexes after TNFa stimulation [27]. Rapid nuclear
export of NF-kB (mainly the p65/p50 dimers) by newly
synthesized IkBa is essential for the post-induction repression
phase of the NF-kB signaling [28,29]. Interestingly, 14-3-3s has
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e38347been categorized as a tumor suppressor in human breast cancers
where is frequently lost due to gene deletion or promoter
methylation [30,31,32,33]. We have now investigated the role of
14-3-3s in breast cancer cells and its putative involvement in the
metastatic phenotype. We have found that 14-3-3s levels
determine the kinetics of nuclear p65 export after TNFa
stimulation and identified a genetic signature that responds to
TNFa in a 14-3-3s-dependent manner. This signature is
significantly associated with breast, intestinal, ovarian and lung
cancer in humans, and its over-expression correlates with poor
relapse-free survival breast cancer patients. Importantly, manip-
ulation of 14-3-3s levels in mammary cells leads to changes in cell
migration in vitro and affects the metastatic capacity of MDA-MB-
231 breast cancer cells in mice. Finally, NF-kB activation is
primarily found in breast tumors lacking 14-3-3s expression and is
significantly associated with reduced disease-free survival of the
patients in uni- and multivariate analysis.
Results
Breast cancer cells with low levels of 14-3-3s show
delayed p65 nuclear export and increased NF-kB activity
To study whether 14-3-3s was involved in NF-kB regulation in
breast cancer cells, we first determined its expression levels in non-
transformed MCF10A and breast cancer (MCF7, MDA-MB-231,
BT-474, SK-BR-3 and T47D) cells. We found that 14-3-3s is
downregulated in cancer cells compared to MCF10A, whereas
other 14-3-3 isoforms show comparable levels. 14-3-3s was also
absent from MDA-MB-435, previously considered as a breast
cancer cells. In contrast, p65 and p50 NF-kB members and their
negative regulator IkBa were similarly expressed in all tested cell
lines (Figure 1A). However, we did not detect any nuclear p65 in
non-stimulated breast cancer cells (Figure 1B).
Since we previously found that 14-3-3 participates in the post-
activation repression of NF-kB [27], we now tested whether
reduced 14-3-3s levels in breast cancer cells affects NF-kB
activation or signal duration. By Electrophoretic Mobility Shift
Assay (EMSA) using specific kB probe, we found sustained nuclear
NF-kB activity in MCF7 and BT-474 and to a minor extent in
MDA-MB-231 breast cancer cells compared to MCF10A cells
after TNFa treatment (Figure 1C). Next, we determined whether
these changes were associated with the capacity of these cells to
retain p65 in the nucleus. By immunofluorescence (IF), we found
that MCF7, MDA-MB-231 and BT-474 cells showed a delay in
redistributing nuclear p65 to the cytoplasm compared with
MCF10A (78%, 63% and 95% of cells containing nuclear p65
compared with 14% in MCF10A cells after 90 min with TNFa)
(Figure 1D). Specificity control for p65 staining was performed
using p65-deficient cells (Figure S1).
p65 binds to 14-3-3s in mammary cells in a TNFa-
dependent manner
We previously showed that TNFa induces p65 binding to 14-3-
3b and 14-3-3g in HEK-293T cells [27]. However, the fact that
14-3-3s deficiency in breast cancer cells correlates with delayed
p65 nuclear export suggests a non-redundant function for this
isoform in mammary cells. By pull-down (PD) we confirmed that
both p65 and p50 isolated from MCF10A cells bound GST-14-3-
3s in response to TNFa. Moreover, this interaction was isoform-
specific since both NF-kB proteins failed to bind 14-3-3g in the
same experiment (Figure 2A). Comparable results were obtained
using cell extracts from different breast cancer cells but not from
MDA-MB-435 (Figure 2B). By coprecipitation experiments we
demonstrated that endogenous 14-3-3s associates with p65 in
response to TNFa in non-transformed mammary cells (Figure 2C
and 2D). Although we cannot formally conclude that the
interaction between 14-3-3s and p65 is direct, the presence of
three 14-3-3-binding sites in the p65 protein [27] strongly suggests
this possibility.
Defective expression of 14-3-3s is responsible for
delayed p65 nuclear export in breast cancer cells
To determine whether 14-3-3s deficiency was responsible for
delayed nuclear export of p65 in breast cancer cells, we generated
pools of MCF7 cells stably expressing the myc-14-3-3s construct
or the control vector (Figure 3A). By IF, we found that ectopic 14-
3-3s enhanced the ability of MCF7 cells to re-export p65 from the
nucleus after TNFa stimulation (Figures 3B and 3C). Moreover,
this effect was not due to changes in endogenous IkBa basal levels,
TNFa-induced degradation of IkBa (that is essential for NF-kB
activation) or IkBa re-synthesis (required for the post-activation
repression of NF-kB) (Figure S2A). Identical results were obtained
using MDA-MB-231 cells (Figures S3A, S3B and S3C) or MCF7
carrying a doxycycline-inducible 14-3-3s construct (Figures S4A
and S4B).
Next, to further study whether reduced levels of 14-3-3s in
tumor cells were responsible for delayed p65 cytoplasmic
redistribution, we knocked-down 14-3-3s in non-transformed
MCF10A cells using three shRNA that resulted in different
degrees of down-regulation (Figure 3D). Reduction of 14-3-3s
levels in MCF10A cells delayed or even blocked p65 export
following chronic TNFa treatment (Figure 3E and 3F) without
affecting IkBa levels (Figure 3D and S2B). These results were
confirmed by subcellular fractionation of the different transduced
cells (Figure 3G).
An NF-kB-dependent transcriptional program depends
on 14-3-3s in breast cancer cells
To investigate whether 14-3-3s levels affect specific NF-kB
dependent transcription in mammary cells, we performed
expression microarray analysis of control or myc-14-3-3s-
expressing MCF7 cells treated with TNFa at different time points
(GSE37139). We distinguished between 4 different groups of
genes: genes induced by TNFa in control cells but not in 14-3-3s-
expressing MCF7 cells (group1); genes induced in both control and
14-3-3s-expressing MCF7 cells (group 2), including differentially
induced genes (group 2.1) or similarly induced genes (2.2). A fifth
group called group 1_2.1 (group 1 plus group 2.1) contains all
genes that were significantly upregulated in TNFa-treated control
cells compared with 14-3-3s-expressing MCF7 cells. Our results
showed that TNFa also induced a similar transcriptional program
in both types of cells (group 2.2), indicating the integrity of the
pathway. Interestingly, a specific set of genes remained unrespon-
sive (group 1), or less responsive (group 2.1) in 14-3-3s-expressing
cells (merged as a single 1_2.1 group for subsequent analysis)
(Figure 4A). These 14-3-3s-dependent genes include well-charac-
terized NF-kB targets such as TNFAIP1, IL8, IL6 or GM-CSF
(Figure 4A and S5). The differential response of some randomly
selected 1_2.1 genes was confirmed by qRT-PCR (Figure S6). A
comparable 14-3-3s-dependent signature was identified in MDA-
MB-231 cells (Figure S7). Furthermore, several 1_2.1 genes
contained multiple NF-kB sites that clustered close to the
transcription start site (TSS) (Figure S8), suggesting that they are
direct NF-kB targets. In this sense, we found that 36 out of 73
genes contained in the 1_2.1 group were significantly downreg-
ulated in p65-knockdown breast cancer cell experiments available
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PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e38347Figure 1. Breast cancer cells with low levels of 14-3-3s show a delay in p65 nuclear export following chronic NF-kB activation. (A)
Western blot analysis of 14-3-3s expression in normal and cancer cell lines. (B) Subcellular fractionation from different mammary cell lines and
western blot analysis with the indicated antibodies. (C) (left panel) TNFa-dependent activation of NF-kB in the indicated cell lines measured by EMSA
and (right panel) densitometric analysis of four independent experiments (average and standard deviation). DNA-binding activity is represented
relative to untreated MCF10A. (D) IF with specific a-p65 antibody of the indicated cells incubated with TNFa at different time points. NUC indicates
cells containing nuclear p65 and CYT, exclusive cytoplasmic staining. A representative of three independent experiments is shown in all cases and all
samples were equally processed.
doi:10.1371/journal.pone.0038347.g001
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shown).
To ask whether the genes in different groups are functionally
related, we performed enrichment analysis with Gene Ontology
terms in the four groups. We found that genes belonging to groups
1 and 1_2.1 are enriched for genes involved in antigen processing
and presentation, protein ubiquitination and regulation of IKK,
while the 14-3-3-independent group 2.2 is enriched in genes
involved in cell cycle and MAPKKK cascade among others.
Moreover, all TNF-responder groups contained genes involved in
NF-kB signaling.
We were also interested in assessing whether genes in 14-3-3s-
dependent signature (group 1_2.1) are miss-regulated in cancer
cells compared to normal cells. For that we used sets of genes
significantly upregulated in different cancer genomic experiments
as obtained from IntOGen [34]. Briefly, IntOGen contains a
collection of independent cancer genomic datasets from different
tumor types, which are processed to identify genes altered in a
significant number of samples. We found that genes in this group
are significantly miss-regulated in different types of tumors
including breast, lung, prostate gland, brain, skin, liver and others
(Figure 4C).
14-3-3s expression modulates breast cancer cell motility
through NF-kB
GO enrichment analysis indicated that 1_2.1 genes were
included in a restricted number of functional categories including
apoptosis, antigen presentation, and stress responses among
others. Thus, we analyzed whether 14-3-3s expression affects
specific biological processes in breast cancer cells. By flow
cytometry analysis, we found comparable proliferation or
apoptotic ratios in control or 14-3-3s-expressing cells (MCF7 or
MDA-MB-231), untreated or treated with TNFa (Figure S9 and
S10). In contrast, wound-healing experiments demonstrated that
MDA-MB-231 cells expressing 14-3-3s showed a reduced motility
compared to the controls (Figure S11) that was comparable to cells
treated with the NF-kB inhibitor BAY11-7082 (Figure S11 and
S12). Conversely, TNFa promotes cell migration concomitant
with nuclear p65 accumulation in the migratory cells (Figure S12).
Similarly, NF-kB inhibition blocked the invasive capacity of
MDA-MB-231 cells in trans-well assays (Figure S13). Next, we
performed wound-healing experiments using control MCF10A
cells and two pools of these cells stably expressing different shRNA
against 14-3-3s (#129 and #132). In these experiments, control
shRNA-transduced MCF10A cells displayed very low migratory
capacity. However, reduction of 14-3-3s levels by shRNA was
sufficient to induce cell migration (Figure S14).
These results suggest that 14-3-3s regulates a specific
transcriptional program, which in turn affects particular cellular
capacities such as cell migration.
Ectopic expression of 14-3-3s reduces the metastatic
capacities of MDA-MB-231 cells
To investigate whether 14-3-3s affects the metastatic breast
cancer phenotype in vivo, we transduced control (MT) or 14-3-3s-
expressing MDA-MB-231 cells with a luciferase reporter construct
and injected them intracardiacally in nude mice (8 animals per
group). Then, we measured the total tumor load and their spatial
distribution by life imaging at different time points after injection
(Figure 5A and 5B). We confirmed that all animals contained
comparable tumor cells at day one after injection, however one
week post injection outgrowths arising in the animals inoculated
with 14-3-3s expressing cells were significantly smaller compared
with those injected with control cells (p=0.007)(Figure 5B). Most
of the metastatic lesions were localized in the bones, specifically in
the tibia and in the femur and were histologically comparable
between the groups, displaying a poorly differentiated phenotype,
nuclear pleomorphism and high mitotic rate (Figure 5C). Inter-
estingly, control cells generated a higher number of bone
metastasis (8/16 legs, 50%) than cells expressing 14-3-3s (5/16
legs, 31%), and IHC analysis of the bones at week 4, when animals
Figure 2. p65 preferentially binds to 14-3-3s in normal and
breast cancer cells following NF-kB activation. (A, B) Pull down
experiment using different GST fusion proteins and cell extracts from
(A) TNFa-treated MCF10 and (B) different breast cancer cell lines.
Densitometric quantification of binding is shown below each panel. (C–
D) Co-immunoprecipitation of endogenous proteins from MCF10A (C)
immunoprecipitation of p65 and detection of 14-3-3s by western blot
and (D) immunoprecipitation of 14-3-3s and detection of p65.
doi:10.1371/journal.pone.0038347.g002
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(Figure 5C) and showed significantly higher numbers of prolifer-
ating cells (Figure 5D, 5E and 5F).
Activation of NF-kB associates with absence of 14-3-3s
and poor prognosis in breast cancer patients
Finally, we examined whether 14-3-3s levels in chemo-naı ¨ve
early human breast tumors correlated with clinical outcome and
Figure 3. Defective 14-3-3s is responsible for delayed p65 nuclear export in breast cancer cells. (A and B) IF analysis of 14-3-3s expression (A)
and p65-NF-kB nuclear translocation (B) in MCF7 control and 14-3-3s expressing cells. (C) Quantification of p65 subcellular distribution in one
representative of 3 independent experiments. (D) Western blot analysis of 14-3-3s levels in MCF10A pools transduced with different shRNA. (E, F)
Representative images of p65 IF (E) and quantification of p65 subcellular distribution in MCF10A cells (F). One representative of three independent
experiments is shown. (G) Subcellular fractionation followed by western blot analysis of p65 in the different MCF10A pools transduced with scrambledo r
14-3-3s-shRNAs. Average of densitometric quantification of 3 independent experiments is shown in the lower panel. For representation of p65 distribution
in 3c and 3f, two groups have been considered, cytoplasmic: homogenous or cytoplasmic staining and nuclear: preferentially nuclear distribution.
doi:10.1371/journal.pone.0038347.g003
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analyzed were negative for 14-3-3s expression, which was
detected at different levels in the normal glands of the same
samples (Figure 6A). However, absence of 14-3-3s did not
correlate with clinical outcome in our series of 96 patients
(Figure 6B). Notably, we detected nuclear p65 in a total of 25
tumor samples (26%), being 24 of them negative for 14-3-3s
(Figures 6C), indicating that NF-kB activation associates with loss
of 14-3-3s in these tumors (p=0.016) (Figure 6D). Importantly,
NF-kB activation in the tumors was associated with reduced
disease-free survival in the univariate analysis of the patients
(Hazard ratio -HR- (95%CI): 3.68 (1.56 to 8.60), p=0.001)
Figure 4. Ectopic expression of 14-3-3s attenuates specific NF-kB-dependent activity in breast cancer cells. (A) Microarray expression
analysis of MCF7 control or 14-3-3s-expressing cells treated with TNFa at the indicated times. Group 1: genes induced by TNFa in control cells but
not in 14-3-3s-expressing MCF7 cells. Group 2: contains genes induced in both control and 14-3-3s-expressing MCF7 cells, including differentially
induced genes (group 2.1). A list including some of the genes identified in the 1_2.1 group (group 1 and 2.1) is shown in the right panel. (B) Selected
Gene Ontology Biological Process terms in an enrichment analysis of 14-3-3s-dependent and independent signatures. Colors towards red indicate
significance; grey indicates no significant enrichment. (C) Enrichment analysis details of genes up-regulated in cancer samples of various experiments
obtained using IntOGen software.
doi:10.1371/journal.pone.0038347.g004
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analysis we found that nuclear p65 was an independent predictor
when adjusted by the rest of significant factors on the univariate
testing. NF-kB activation showed the highest risk for relapse
compared to the tumor grade or the presence of infiltrated lymph
nodes (p,0.001, Hazard Ratio of 8.89, 6.68 and 6.15, respec-
tively) (Table 1). Analysis of breast cancer experiments containing
both microarray expression and clinical data demonstrated that
patients with tumors over-expressing the 14-3-3s-dependent
signature showed a poorer relapse-free survival compared with
the rest of the patients (p=0.00917)(Figure 6F) (experiment
GSE12276) [35]. Together our data indicates that pro-tumori-
genic effects of 14-3-3s deletion in breast cancer are associated
with its role as an NF-kB regulator.
Discussion
We have identified 14-3-3s as a negative regulator of NF-kBi n
breast cancer and demonstrated that loss of 14-3-3 expression is
directly associated with the capacity of breast cancer cells to
metastasize.
Chronic NF-kB activation has been involved in many types of
cancer, mostly associated with immune cell infiltration, which
express pro-inflammatory cytokines that activate the pathway in
the epithelial cells [16,36,37,38]. In agreement with this, most of
the tumor-related effects of NF-kB activation, for example in liver
and intestine, are generally attenuated by specific abrogation of
the pathway in the immune cells [39,40]. Similarly, NF-kB activity
in breast cancer metastasis are likely induced by infiltrating T-cells
[16] in contrast to the cell autonomous activation of NF-kB
downstream of Src [41], Her2 [42] or by mutation of p53 [43].
The convergence of different oncogenic pathways on NF-kB opens
the possibility to specifically target this transcription factor or other
elements of the pathway for therapeutical intervention in breast
cancer, a strategy that is currently tested in patients with cancer-
related bone metastases using proteasome inhibitors (18454159) or
antibodies against RANKL [PMID 21060033, 17785705,
19237632] ([44].
We previously demonstrated the involvement of 14-3-3b and
14-3-3g proteins in p65 nuclear export after TNFa activation in
HEK-293T cells [27]. We now showed that 14-3-3s plays a non-
redundant function in mammary cells facilitating p65 nuclear
export, although we cannot exclude other mechanisms that affects
intracellular distribution of p65. In agreement with this, activation
of NF-kB was specifically found in human tumors lacking 14-3-3s.
Deletion of 14-3-3s has been consistently associated with breast
cancer as it plays tumor suppressor functions in this [45] and other
types of cancer [46,47]. We have now demonstrated that absence
of 14-3-3s expression by itself does not correlate with poorer
clinical outcome, but it is absolutely required for NF-kB activation,
which is intimately related with patient relapse and clinical
outcome. This finding indicates that despite the important
functions of 14-3-3 as a regulator of CDC25, p53, FOXO, raf-1
or mTOR among others, modulation of the NF-kB pathway is the
link between loss of 14-3-3s and breast cancer patient outcome. In
addition, we have identified a specific signature downstream of
TNFa that depends on 14-3-3s including previously characterized
NF-kB-target genes such as IL6, IL8, GM-CSF or A20. The
mechanisms underlying this gene specificity are still unknown but
it could be related with the presence of specific histone
modifications in the promoter of these genes [48]. Moreover,
since TNFa activates other pathways such as JNK or the caspase
cascade [49], we cannot exclude that 14-3-3s-dependent signature
includes some NF-kB-independent genes. In any case, 14-3-3s-
regulated genes affect the acquisition of specific capacities such as
cell migration and bone metastasis in vivo, and its over-expression
correlates with disease-free survival in breast cancer patients.
Considering the current availability of high throughput
sequencing technology in clinical practice, our results are of
critical importance for future stratification of breast cancer
patients for personalized treatments.
Materials and Methods
Ethics Statement
Human tissue samples were obtained from the archive of The
Pathology Department of Hospital del Mar with the approval of
the Bank Tumor Committee, according to the Spanish Ethical
regulations. This study was approved by the local Ethics Board
(Clinical Research Ethical Committee of the Parc de Salut Mar,
CEIC-IMAS2009/3515/) and followed the guidelines of the
Declaration of Helsinki and patient identity of the pathological
Figure 5. Re-expression of 14-3-3s in MDA-MB-231 cells
inhibits bone metastasis in vivo. (A) Representative biolumines-
cence images of mice injected with 0.5610
6 control or 14-3-3s-
overexpressing MDA-MB-231 cells 4 weeks after intracardiac injection.
(B) Scattered plot of the dorsal photon flux (normalized to Day 0) at
different times after injection. Each symbol represents one animal (C–D)
H&E staining and IHC for 14-3-3s (C) and IHC for ki-67 (D) of a
representative bone-metastasis from a mouse injected with control
(MT) or 14-3-3s-expressing cells. (E–F) Quantification of cells expressing
the proliferation marker ki-67 (E) and number of mitotic figures in the
H&E staining (F) determined by counting 10 different high power fields
per tumor (3 tumors counted for each group).
doi:10.1371/journal.pone.0038347.g005
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Informed written consent was obtained from all subjects.
All animal work has been performed at IRB, Parc Cientı ´fic,
Barcelona and followed the protocols approved by the Animal
Care and Use Committee from Parc Cientı ´fic de Barcelona.
Decree 214/1997 regulates the use of animals for research. Along
these lines the Autonomous Government of Catalonia approved
the Animal Welfare Committee of the Parc Cientı ´fic de Barcelona,
responsible for evaluating activities undertaken in the centre.
Cell lines and cultures
Seven human breast cancer cell lines (MDA-MB-231, MDA-
MB-453, MDA-MB-468, SK-BR-3, BT-474, MCF-7 and T47D),
a human cervical cancer cell line (HeLa) and a mammary
epithelial one as control (MCF-10A) were purchased from the
American Type Culture Collection and cultured at 37uC with 5%
CO2 in DMEM (MDA-MB-231, MDA-MB-453, MDA-MB-468,
BT-474, SK-BR-3, MCF-7, 2 supplemented with 10% fetal bovine
Figure 6. 14-3-3s-dependent NF-kB activity correlates with poor prognosis in breast cancer patients. (A) Representative tumors
showing different patterns of 14-3-3s expression, that was distributed both in cytoplasm and nucleus of tumor cells. Consistently, positive 14-3-3s
staining was observed in myoepithelial cells of normal ducts and ductal carcinoma in situ (arrowheads). (B and E) Kaplan-Meier curves depict
cumulative disease-free survival of breast cancer patients stratified by the absence of 14-3-3s (B) and by the presence of nuclear p65 (E). (C) Double IF
of representative breast tumors showing that nuclear p65 distribution was restricted to the 14-3-3s negative samples (D) Cross-tabulation of 14-3-3s
expression and NF-kB activation (as determined by nuclear p65) in the different tumors analyzed. (F) Kaplan-Meier curve depict relapse-free survival
of breast cancer patients stratified by up-regulation of 14-3-3s-dependent signature in the primary tumors.
doi:10.1371/journal.pone.0038347.g006
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10A was cultured in MEMB Basal Medium (Clonetics, cat.
No. CC-3151) supplemented with MEGM Singlequots (Clonetics,
cat. No. CC-4136): 2 ml BPE, 500 ng/ml hydrocortisone, 10 ng/
ml hEGF and 5 mg/ml insulin. Cell lines were transfected using
PPEI (PolySciences).
Antibodies and Reagents
Anti p65 (sc-109 and sc-372), p50 (sc-7178), IkBa (sc-371),
PAN-14-3-3 (sc-629), 14-3-3b (sc-17288) and 14-3-3s (sc-7681
and sc-7683) were from Santa Cruz. a-a-tubulin was from Sigma,
and a-ki67 from Novocastra. Secondary HRP-conjugated anti-
bodies were from DAKO and fluorescein-conjugated secondary
Table 1. Relapse-free survival analysis.
Univariate (n=96) Multivariate (n=96)
HR 95% CI P HR 95% CI P
Variable
Age 0.269
Premenopausal 1.00 -
Postmenopausal 0.44 0.10 to 1.89 -
Tumor size, mm 0.020 0.167
#20 1.00 1.00
21–50 3.85 1.47 to 10.07 2.41 0.80 to 7.25
.50 1.77 0.35 to 8.81 1.74 0,73 to 7.54
Tumor grade 0.007 0.024
I 1.00 1.00
II 2.29 0.48 to 10.86 1.76 0.34 to 9.25
II 7.02 1.56 to 31.46 6.68 1.15 to 38.75
Lymph nodes 0.006 0.007
None 1.00 1.00
1–3 1.22 0.39 to 3.80 0.63 0.19 to 2.17
4–9 0.38 0.49 to 2.93 1.33 0.30 to 3.06
.9 5.64 1.96 to 16.22 6.16 1.49 to 25.39
Histology 0.603
Ductal 1.00 -
Lobular 0.91 0.54 to 2.51 -
Others 1.01 0.32 to 2.74 -
Hormonal receptor status 0.002 0.402
Negative 1.00 1.00
Positive 0.27 0.11 to 0.62 0.63 0.22 to 1.84
HER2 status 0.062
Negative 1.00 -
Positive 1.89 0.94 to 5.59 -
Proliferation (Ki67) 0.022 0.057
Low proliferation 1.00 1.00
High proliferation 2.71 1,15 to 6.34 2.88 0.97 to 8.56
Adjuvant chemotherapy 0.396
No 1.00 -
Yes 0.68 0.28 to 1.64 -
Adjuvant hormonotherapy 0.151
No 1.00 -
Yes 0.54 0,23 to 1.26 -
p65-NF-kB 0.001 ,0.001
Cytoplasmic expression 1.00 1.00
Nuclear expression 3.68 1.56 to 8.60 8.89 2.99 to 26.39
Abreviations: DFS, disease free survival; HR, hazard ratio; CI, confidence interval; HER2, human epidermal growth factor receptor 2.
Relapse free survival analysis of the group of patients that were studied for the presence of nuclear p65. Commonly used clinical predictors such as tumor grade and
size, or the number of infiltrated lymph nodes were studied in comparison with the status of p65.
doi:10.1371/journal.pone.0038347.t001
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used at 100 mM and BAY65-5811 is a gift from Bayer. TNFa from
Preprotech was used at 40 ng/ml.
Pull-down Assays
PD assays were performed as previously described [50], Briefly,
GST fusion proteins were purified and incubated with cell lysates
for 45 min in a rotary shaker at 4uC. Precipitates were washed and
analyzed by western blot.
Subcellular fractionation and western blotting
For cytoplasm-nuclear separations, cells were lysed in 10 mM
HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.05%NP40 at pH 7.9,
10 min on ice and centrifuged at 3.000 rpm. Supernatants were
recovered as cytoplasmic fraction and the pellets lysed in 5 mM
HEPES, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT and
26% glycerol and sonicated 5 min three times to recover the
soluble nuclear fractions. Protein lysates were run in SDS/PAGE
and transferred to immobilon-P transfer membranes (Millipore).
Membranes were blocked with 4% dehydrated milk and blotted
with the indicated antibodies O/N at 4uC. Secondary HRP-linked
secondary antibodies were developed using the ECL system from
Amersham.
Coimmunoprecipitation assays
Precipitations were performed in 500 ml of PBS containing
0.5% Triton X-100, 1 mM EDTA, 100 mM sodium orthovana-
date, 0.2 mM PMSF, 20 mM b-glycerophosphate and complete
protease inhibitor cocktail (Roche). Lysates were incubated for
2 hours at 4uC with primary antibodies coupled to Protein A-
Sepharose beads, washed and analyzed by western blot.
Immunofluorescence
Cells were fixed in 4% paraformaldehyde and permeabilized
with 0.3% Triton X-100 and 4% non-fat dry milk in PBS. Primary
antibodies were incubated overnight and secondary antibodies for
90 min. Slides were mounted in Vectashield with DAPI (Vector)
and visualized in an Olympus BX61. Images were analyzed using
the Cell ˆB Software from Olympus.
Immunohistochemistry (IHC)
Paraffin-embedded 4 mm sections were kept one hour at 60uC
and re-hydrated. Antigen retrieval was done in citrate buffer
(pH 6.0) at 80uC, and primary antibodies were incubated
overnight at 4uC. Samples were washed in ChemMate buffer
solution and developed with Envision signal detection system
(DAKO). Two investigators, blinded to clinical data, scored each
sample, for nuclear p65 and 14-3-3s staining. Concordance
between investigators was higher than 95%.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared as described [51]. Briefly, 3 mg
of the indicated nuclear extracts were incubated with labeled
double-stranded kB-binding consensus oligonucleotide (5-AGTT-
GAGGGGACTTTCCCAGGC-3) 15 min at room temperature
in a final volume of 20 mL. Samples were run in 0.5% tris–borate–
EDTA buffer on non-denaturating 4% polyacrylamide gels, which
were vacuum-dried and subjected to autoradiography. Densito-
metric analysis of the bands was performed using the Adobe
Photoshop CS4 software.
qRT-PCR
Total RNA was isolated using RNeasy kit (Qiagen) and cDNA
was obtained with RT-First Strand cDNA Synthesis kit (Amer-
sham). qRT-PCR was performed in LightCycler 480 system sing
SYBR Green I master kit (Roche).
Microarray experiment
Control or 14-3-3s-reconstituted MCF7 cells were incubated
with TNFa for 0, 20 and 90 min in two independent experiments.
RNA was obtained and RNA integrity assessed using Agilent 2100
Bioanalyzer (Agilent Technologies, Palo Alto, CA). All samples
had an RNA integrity number (RIN)$8.5. Amplification, labeling
and hybridizations were performed according to protocols from
Ambion and Affymetrix. Briefly, 250 ng of total RNA were
amplified using the AmbionH WT Expression Kit (Ambion/
Applied Biosystems, Foster City, CA, USA), labeled using the WT
Terminal Labeling Kit (Affymetrix Inc., Santa Clara, CA, USA),
and then hybridized to Human Gene 1.0 ST Array (Affymetrix) in
a GeneChipH Hybridization Oven 640. Washing and scanning
were performed using the Hybridization Wash and Stain Kit and
the GeneChipH System of Affymetrix (GeneChipH Fluidics Station
450 and GeneChipH Scanner 3000 7G).
Microarray data processing
Microarray data was processed with R statistical framework
[52]. Aroma.affymetrix [53], corpcor [54] and Limma [55]
packages were used to preprocess, batch adjust and determine
the top 220 most differentially expressed genes across conditions
with an adjusted p-value (False Discovery Rate, FDR) ,0.05 [56].
The analysis was designed to identify genes that were induced by
TNFa in control cells but not in 14-3-3s-expressing MCF7 cells
(group 1); genes induced in both control and 14-3-3s-expressing
MCF7 cells (group 2) including genes that were differentially
induced in control and 14-3-3s-expressing MCF7 cells (group
2.1). Groups 1 and 2.1 were included as 1_2.1 in subsequent
analysis. Values represented for each probe set correspond to
standard deviations after mean-centering the values in each row.
Hierarchical clustering was performed on samples and also on the
220 most differentially expressed genes using Pearson correlation
as distance measure and the average method, and the obtained
clusters were used to generate the groups of genes for further
analysis.
Functional enrichment analysis of 14-3-3s gene
signatures
We performed enrichment analysis (EA) of the different groups
(see microarray data processing) with Gene Ontology terms. This
analysis reveals the enrichment of a particular functional term in a
group of genes. The EA was done with binomial test using Gitools
[57], a statistical framework for the analysis and visualization of
genomics data. The annotation of genes to corresponding Gene
Ontology Biological Process, Cell Location and Molecular
Function terms were downloaded from Ensembl version 60 [58]
using Gitools importer. The p-values resulting from the binomial
test were adjusted for multiple testing using the Benjamini and
Hochberg’s method of FDR and we set the cut-off for significance
at a 0.05 of the corrected p-value. Results are represented in a
heat-map of p-values where colors towards red indicate signifi-
cance and grey indicates no significant enrichment.
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gene modules
To test whether genes in the 14-3-3s-dependent signature
(group 1_2.1) are enriched in cancer samples, we used sets of genes
significantly upregulated in different cancer genomic experiments
as obtained from IntOGen [34]. Briefly, IntOGen contains a
collection of independent cancer genomic datasets from different
tumor types, which are processed to identify genes altered in a
significant number of samples. Enrichment analysis was performed
with Gitools as explained above.
Relapse-free survival analysis
To test whether expression of genes in the 14-3-3s dependent
signature correlates with tumor relapse we used Sample Level
Enrichment Analysis (SLEA) as described in Gundem and Lopez-
Bigas 2012 [53] with a dataset containing 204 primary tumors
from breast cancer patients with known site of relapse (GEO id
GSE12276, [35]. Briefly, SLEA assesses the transcriptional status
of a set of genes in each sample using Z-score test (see [53] for
details), the result is a Z-score per sample indicating the
transcriptional status of the gene set in each sample. High Z-
scores indicate that the set of genes tend to have high expression,
low Z-scores indicate that the set of genes tend to have low
expression and Z-scores around 0 indicate that they do not show a
clear tendency to be misregulated in any direction. We used the Z-
score to stratify the 204 samples according to the expression levels
of genes in 14-3-3s dependent signature and generated two
groups: samples with significant up-regulation of 14-3-3s depen-
dent signature (n=38) and the rest of samples (n=166). Analysis
of the relapse-free survival of patients in the two groups was
performed using R Bioconductor survival package [52,59].
Metastasis Assay in nude mice
A cell suspension of 0.5610
6 MDA-MB-231 breast cancer cells
was injected in the left cardiac ventricle of anesthetized 6–7-week-
old nude mice. Tumor development was monitored by weekly
bioluminescence imaging using the IVIS-200 imaging system from
Xenogen [60]. Bone metastatic lesions were localized by ex vivo
bioluminescence imaging and confirmed by histological analysis
after necropsy. Bones were decalcified, fixed and processed for
histological analysis (Hematoxylin & Eosin staining, H&E) and
IHC. All animal work followed the protocols approved by the
Animal Care and Use Committee of the Barcelona Science Parc.
Computational promoter analysis
Presence of NF-kB binding sites in the promoters of interest
(from 23000 bp to +100 bp to the transcription start site (TSS))
was predicted using the Genomatix software.
Supporting Information
Figure S1 Immunofluorescence with specific a-p65-NF-
kB antibody (sc-109) of wildtype and p65-deficient
mouse embryonic fibroblasts incubated with TNFa at
the indicated times.
(TIF)
Figure S2 (A, B) Western blot analysis of IkBa expres-
sion in the indicated cell lines untreated or treated with
TNFa.
(TIF)
Figure S3 (A) Immunofluorescence with specific a-p65-
NF-kB antibody of MDA-MB-231 control or 14-3-3s-
expressing (clone#34) cells incubated with TNFa at the
indicated times. (B) Quantification of p65-NF-kB subcellular
distribution determined by Immunofluorescence in one represen-
tative of three independent experiments: cytoplasmic: homogenous
or cytoplasmic staining and nuclear: preferentially nuclear
distribution. (C) Western blot analysis of 14-3-3s expression in
different cell clones.
(TIF)
Figure S4 (A) Immunofluorescence (upper panel) and
western blot analysis (lower panel) of 14-3-3s expression
in MCF7 cells carrying a doxycycline-inducible con-
struct, untreated or treated with doxycycline for 16 h. (B)
Quantification of p65-NF-kB subcellular distribution in these cells
in one representative experiments (from three independent
experiments): cytoplasmic: homogenous or cytoplasmic staining
and nuclear: preferentially nuclear distribution.
(TIF)
Figure S5 List of genes included in groups 1 and 2.1.
(TIF)
Figure S6 Quantitative PCR analysis of MCF7 cells
carrying a doxycycline-inducible 14-3-3s construct to
confirm the effects in the TNFa-dependent expression of
randomly selected genes from 1.2.1 group.
(TIF)
Figure S7 Quantitative PCR analysis of randomly
selected genes from 1.2.1 group in control or 14-3-3s-
expressing MDA-MB-231 cells.
(TIF)
Figure S8 Analysis of gene promoters using the Geno-
matix software to determine the presence of NF-kB
binding sites in the selected 14-3-3s-dependent genes.
(TIF)
Figure S9 Cell-cycle profiles (A) and apoptotic ratios as
determined by AnexinV-binding (B) on control and 14-3-
3s-expressing MCF7 cells.
(TIF)
Figure S10 Cell-cycle profiles (A) and apoptotic ratios as
determined by AnexinV-binding (B) on control and
different 14-3-3s-expressing MDA-MB-231 cell clones.
(TIF)
Figure S11 Wound-healing assay using control or 14-3-
3s-expressing MDA-MB-231 cells. Specific IKK inhibitor
BAY11-7082 was used to inhibit NF-kB activity.
(TIF)
Figure S12 Representative wound-healing assay using
MDA-MB-231 and MCF7 cells untreated or treated with
the IKK inhibitor BAY11-7082 or with TNFa at the
beginning of the experiment. Immunofluorescence with a-
p65-NF-kB antibody showing nuclear p65-NF-kB translocation in
the migrating cells (right panel).
(TIF)
Figure S13 Effects of blocking NF-kB activity with two
different IKK inhibitors (BAY11-7082 and BAY65-5811)
on the migratory capacity of MDA-MB-231 cells in
transwell experiments.
(TIF)
Figure S14 Wound-healing assay using control MCF10A
cells or cells transduced with different shRNA against
14-3-3s.
(TIF)
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